arch-venture-partners
(2)
Sabah Oney
Sabah Oney is the president and CEO of Dispatch Bio, a Philadelphia- and San Francisco-based biotech engineering a universal treatment for solid tumors using CAR-T cell therapy. Born in Cyprus and in the U.S. since age 18, he holds a genetics degree from the University of Kansas, a PhD in genetics and genomics from Duke, and an MBA from Stanford. Across nearly two decades in biotech he helped scale Ariosa Diagnostics (acquired by Roche), took Alector public as its chief business officer, co-founded Vilya, and served as a venture partner at ARCH. Dispatch launched publicly in 2025 with $216 million behind its FLARE platform and CAR-T pioneer Carl June among its founders.
Jason Ehrlich
Jason Ehrlich is the co-founder and CEO of Ollin Biosciences, an Austin-based clinical-stage biopharma launched in September 2025 with $100 million to build best-in-disease eye medicines. An MD-PhD ophthalmologist trained at Princeton and Stanford, he spent a decade at Genentech/Roche helping shepherd retina drugs including Lucentis and the bispecific faricimab (Vabysmo), then served five years as chief medical and development officer at Kodiak Sciences. At Ollin he is taking direct aim at the market leader: in early 2026 his lead asset OLN324 beat faricimab head-to-head in a randomized Phase 1b study, drying retinas faster and deeper with a clean safety record.